证券代码：300006 证券简称：莱美药业 公告编号：2025-029 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重庆莱美药业股份有限公司（以下简称"公司"）于2025年2月21日在巨潮 资讯网（www.cninfo.com.cn）披露了《关于持股5%以上股东所持部分股份被动 减持的预披露公告》（公告编号：2025-003），公司持股5%以上股东邱宇因与国 海证券股份有限公司（以下简称"国海证券"）开展质押式证券回购业务相关债 务逾期，国海证券拟通过集中竞价方式继续处置邱宇持有的67.48万股公司股份， 上述减持计划自披露之日起15个交易日后的3个月内进行，且任意连续90个自然 日内通过集中竞价交易减持股份的总数不超过公司股份总数的1%。 公司于近日收到股东邱宇出具的《关于股份被动减持计划期限届满的告知 函》，获悉持股5%以上股东邱宇本次减持计划期限已届满。根据《上市公司股东 减持股份管理暂行办法》《深圳证券交易所上市公司自律监管指引第18号——股 东及董事、高级管理人员减持股份》等有关规定，现将减持计划实施情况公告如 下： 一、股东被动减持情况 股东 减持股数 减持均价 减持价格区 ...

Group 1 - Chengjian Development received a dividend of 7.1282 million yuan from Beijing Jingcheng Jiaye Property Co., Ltd., in which it holds a 33.47% stake [1] - Shengnuo Bio expects a net profit attributable to shareholders of 77.0275 million to 94.1448 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - JKN2301 dry mixed suspension has been approved for clinical trials, targeting children with influenza [5][6] Group 2 - Jindawei obtained a patent for a method of purifying natto kinase, with a validity of twenty years [2] - CITIC Guoan plans to increase its stake in China Broadcasting Hunan Company to approximately 5.29% through a capital increase of 278 million yuan [2] - Ji Electric announced the resignation of its general manager, Niu Guojun, due to work changes [3] Group 3 - Xintian Green Energy successfully issued 1.5 billion yuan in green medium-term notes with a term of 3+N years and an interest rate of 2.05% [7] - Hengrun Co. plans to invest 1.2 billion yuan in a project to produce 2,000 sets of wind turbine gearbox components [9] - Pulaide received a government subsidy of 10 million yuan, accounting for 15.87% of its audited net profit for the last fiscal year [10] Group 4 - Boteng Co. passed the EU QP audit, receiving a compliance statement for its CDMO services [12] - Zhou Dasheng added 7 self-operated stores in May, with total investments ranging from 900,000 to 6.5 million yuan [13] - Wantai Bio initiated a Phase III clinical trial for its live attenuated varicella vaccine [15] Group 5 - Shanghai Pharmaceuticals received a drug registration certificate for Pregabalin capsules in Thailand [19] - Sanxing Medical's subsidiary is expected to win contracts worth approximately 143 million yuan from State Grid projects [21] - Jiangsu Huachen plans to issue 460 million yuan in convertible bonds [24] Group 6 - Jian Gong Repair won a soil pollution remediation project worth 32.76 million yuan [25] - Dize Pharmaceutical completed patient enrollment for a global Phase III clinical trial of its drug [26] - Del Co. received acceptance for its application to issue shares for asset acquisition and raise matching funds [27] Group 7 - Beijing Kerui won multiple power grid projects with a total value of approximately 154 million yuan [27] - Xie Chuang Data signed financing lease contracts totaling 498 million yuan with Su Yin Financial Leasing [28] - Meige Intelligent submitted an application for H-share listing on the Hong Kong Stock Exchange [29][31] Group 8 - Aikodi plans to repurchase shares worth 100 million to 200 million yuan for employee stock ownership plans [54] - Kong Kong Industrial intends to sell 80% of Tianyuan Construction to its controlling shareholder [55] - Youyou Green Energy proposed a cash dividend of 12 yuan per 10 shares, totaling 50.4 million yuan [55]

证券代码：300006 证券简称：莱美药业 公告编号：2025-030 重庆莱美药业股份有限公司 关于持股 5%以上股东所持部分股份 被动减持的预披露公告 公司持股 5%以上股东邱宇保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 2、截至本公告日，邱宇持有公司股份 110,705,915 股，占公司总股本的 10.48%。 二、本次减持计划的主要内容 1、股东名称：邱宇 2、减持原因：因邱宇与国海证券质押式证券回购业务相关债务逾期，国海 证券将通过集中竞价方式继续减持邱宇持有的 5,915 股公司股份（占公司总股本 的 0.00056%）。 1、重庆莱美药业股份有限公司（以下简称"公司"）持股 5%以上股东邱宇 因与国海证券股份有限公司（以下简称"国海证券"）开展质押式证券回购业务 相关债务逾期，国海证券拟依据广西壮族自治区南宁市青秀区人民法院出具的 《协助执行通知书》，将通过集中竞价方式继续处置邱宇持有的 5,915 股公司股 份（占公司总股本的 0.00056%）。本次减持计划自本公告披露之 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-029 重庆莱美药业股份有限公司 关于持股 5%以上股东被动减持期限届满的公告 | 股东 | | | 本次被动减持前持有股份 | | 本次被动减持后持有股份 | | --- | --- | --- | --- | --- | --- | | 名称 | 股份性质 | 股数（万 | 占总股本比例 | 股数（万 | 占总股本比例 | | | | 股） | | 股） | | | 邱宇 | 合计持有股份 | 11,137.48 | 10.55% | 11,070.59 | 10.48% | 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重庆莱美药业股份有限公司（以下简称"公司"）于2025年2月21日在巨潮 资讯网（www.cninfo.com.cn）披露了《关于持股5%以上股东所持部分股份被动 减持的预披露公告》（公告编号：2025-003），公司持股5%以上股东邱宇因与国 海证券股份有限公司（以下简称"国海证券"）开展质押式证券回购业务相关债 务逾期，国海证券拟通过集中竞价方式继续处置邱宇持有的67.48万股公司股份， 上述减持计 ...

Group 1 - The company, Chongqing Laimei Pharmaceutical Co., Ltd., announces that its indirect controlling shareholder, Guangxi Investment Group Co., Ltd., plans to increase capital in Guangxi Investment Group Financial Holding Co., Ltd. by transferring 859,343,587 shares of its direct controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd., which accounts for 25.94% of Zhongheng Group's total share capital [1][2] - After the transaction, Guangxi Investment Group Financial Holding Co., Ltd. will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the actual controller will still be the Guangxi State-owned Assets Supervision and Administration Commission [1][2] - The transaction is still in the planning stage and requires approval from state-owned assets authorities and other legal procedures [1][3] Group 2 - Prior to the transaction, Zhongheng Group is the direct controlling shareholder, and Guangxi Investment Group is the indirect controlling shareholder, with the actual controller being the Guangxi State-owned Assets Supervision and Administration Commission [2] - The transaction will not affect the company's normal production and operational activities, as it is a change of state-owned equity under the same control [2]

证券代码：300006 证券简称：莱美药业 公告编号：2025-028 重庆莱美药业股份有限公司 关于控股股东股权结构拟发生变动的提示性公告 本公司、董事会全体成员及相关股东保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 重庆莱美药业股份有限公司（以下简称"公司"） 间接控股股东广西投 资集团有限公司（以下简称"广投集团"）拟以其所持有的公司直接控股股东广 西梧州中恒集团股份有限公司（以下简称"中恒集团"）859,343,587 股股份（占 中恒集团总股本的 25.94%）对广投集团下属控股子公司广西投资集团金融控股 有限公司（以下简称"广投金控"）进行增资扩股（以下简称"本次交易"）。 本次交易属于同一控制下的国有股权变动。本次交易完成后，广投金控 将变为公司间接控股股东，中恒集团仍为公司直接控股股东，广西壮族自治区国 有资产监督管理委员会（以下简称 "广西国资委"）仍为公司实际控制人。 上述股权变动事项尚处于筹划阶段，尚需履行国资审批程序及相关法定 程序。截至本公告披露日，广投集团与广投金控尚未签订相关协议。敬请广大投 资者理性投资并注意投资风险。 二、本次交易 ...

Group 1 - The core point of the article is that the indirect controlling shareholder of Laimei Pharmaceutical, Guangtou Group, plans to increase capital in Guangtou Jinkong by using its 859 million shares of Zhongheng Group, which accounts for 25.94% of Zhongheng Group's total share capital [1] - This transaction is classified as a change in state-owned equity under the same control [1] - After the completion of the transaction, Guangtou Jinkong will become the indirect controlling shareholder of Laimei Pharmaceutical, while Zhongheng Group will remain the direct controlling shareholder [1] Group 2 - The actual controller of Laimei Pharmaceutical will still be the Guangxi State-owned Assets Supervision and Administration Commission [1] - The equity change is currently in the planning stage and requires approval from state-owned assets authorities and other legal procedures [1]

Group 1 - The hepatitis concept sector declined by 1.36%, ranking among the top declines in concept sectors, with major declines seen in companies like Hai Chen Pharmaceutical, Hainan Hai Pharmaceutical, and Nuotai Biological [1][2] - Among the 18 stocks that rose, Fu Rui Co., Ltd., Fozi Pharmaceutical, and *ST Shuangcheng led with increases of 6.42%, 5.79%, and 5.03% respectively [1][2] - The hepatitis concept sector experienced a net outflow of 859 million yuan from main funds, with 88 stocks seeing net outflows, and five stocks exceeding 50 million yuan in outflows [2][6] Group 2 - Hai Chen Pharmaceutical had the highest net outflow of main funds at 119 million yuan, followed by Zhongsheng Pharmaceutical, Nuotai Biological, and Lu Kang Pharmaceutical with outflows of 95.25 million yuan, 92.01 million yuan, and 88.21 million yuan respectively [2][6] - The stocks with the highest net inflows included Fu Rui Co., Ltd., Zhongheng Group, and Te Bao Biological, with inflows of 52.72 million yuan, 39.98 million yuan, and 37.06 million yuan respectively [2][6]

今日焦点中国中车：近期签订合计547.4亿元重大合同 中国中车公告称，公司及下属企业于近期（主要为2024年12月至2025年5月）签订了若干项重大合同， 合计金额约547.4亿元人民币。主要合同包括城市轨道车辆、设备销售及维保合同，动车组销售合同， 动车组高级修合同，风电设备销售合同和储能设备销售合同，机车销售合同以及货车修理合同。上述合 同总金额约占公司中国会计准则下2024年营业收入的22.2%。 阳光诺和：拟购买朗研生命100%股权，股票明日复牌 南方财经5月12日电，阳光诺和(688621.SH)公告称，公司拟通过发行股份及可转换公司债券购买资产并 募集配套资金，购买利虔、朗颐投资等38名朗研生命股东持有的朗研生命100%股权。并向不超过35名 特定投资者发行股份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外 提供药品生产服务，在高端化学药、原料药等领域深耕多年，已经形成了较为成熟的医药生产体系。公 司股票将于5月13日开市起复牌。 沃尔核材：筹划发行H股股票并申请在香港联交所主板上市 沃尔核材公告称，公司拟发行H股股票并申请在香港联交所主板挂牌上市，以推进国际化战略，提升 ...

Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]